Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer

By afschroeder • August 18, 2026

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko M, Majure M, Tsai K, Kordic A, Chien J, Mortimer J, Rugo HS, Lechner MG, Blaes A, McCann KE. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2026 Jul 20;26(9):91-100. doi: 10.1016/j.clbc.2026.07.026. Epub ahead of print. PMID: 42607491.

Tags: Endocrinology, Hematology/Oncology, immune checkpoint inhibitor, immunotherapy, PD-1 PD-L1 inhibitor, Publications, toxicity

Compartment-Specific Recurrence in Medullary Thyroid Cancer

Seo YJ, Larios KN, Mao YV, Elkersh YK, England B, Hughes EG, Lim AN, Kim J, Livhits MJ, Yeh MW, Angell TE, Hu-Bianco QL, Lee[...]

A Case of Thyroid Dermopathy

Day AJ, Sarantopoulos GP. A Case of Thyroid Dermopathy. Cureus. 2026 Jul 29;18(7):e113624. doi: 10.7759/cureus.113624. PMID: 42668724; PMCID: PMC13525185.

Afirma Xpression Atlas Alteration Status Is Associated with Malignancy Risk in Indeterminate Thyroid Nodules

Peng TD, Hughes EG, Kim J, Tseng CH, SmookePraw S, Wu JX, Yeh MW, Livhits MJ. Afirma Xpression Atlas Alteration Status Is Associated with Malignancy[...]